Fertility Clinic EBITDA Multiples: 5x–9x — What Buyers Pay (2026)
What drives premium valuations for IVF practices and how private equity platforms like US Fertility and CCRM price acquisitions in today's consolidating market.
Fertility clinics trade at 5x–9x EBITDA in lower middle market M&A, reflecting strong demand from PE-backed platforms, limited supply of SART-accredited practices, and durable cash flow from self-pay IVF and egg freezing services. Single-physician practices command the low end; multi-RE clinics with diversified revenue attract aggressive bids near the top of the range.
Fertility Clinic EBITDA Multiples (2026)
| Practice Size | EBITDA Range | Multiple Range | Notes |
|---|---|---|---|
| Single-Physician, Basic IVF | $1.5M–$2M | 5x–6x | One RE, no associate, limited service lines, average or unpublished SART rates. High key-person risk reduces buyer confidence and pricing. |
| Established Two-Physician Practice | $2M–$3M | 6x–7x | Two board-certified REs, in-house IVF lab, SART membership, moderate self-pay mix. Suitable for regional network add-on acquisition. |
| Multi-Service Fertility Center | $3M–$4.5M | 7x–8x | Donor egg, PGT-A, egg freezing, and employer benefit contracts. Above-average SART success rates and clean regulatory history command this range. |
| Platform-Ready Regional Clinic | $4.5M+ | 8x–9x | Multiple REs, Progyny or WINFertility contracts, modern accredited lab, strong brand. Ideal platform for PE rollup commanding top-of-market pricing. |
Valuation Drivers — What Makes Your Multiple Higher or Lower
The spread between 3.5x and 6.5x is not random. These seven factors determine where your firm lands.
SART/CDC Success Rate Publication
High PositiveClinics publishing above-average live birth rates attract more self-pay patients and signal quality to buyers, directly supporting premium multiples and reducing due diligence risk.
Single-Physician Dependency
High NegativeA solo RE with no associate or succession plan introduces catastrophic key-person risk. Buyers apply 1x–2x multiple discount or require extended earnouts to mitigate.
Diversified Revenue Streams
Moderate PositiveAdding egg freezing, PGT-A genetic testing, donor egg programs, and male fertility services expands revenue and reduces IVF cycle volume concentration risk.
Employer Fertility Benefit Contracts
High PositiveLong-term agreements with Progyny or WINFertility provide contracted, recurring patient volume, improving revenue predictability and justifying higher valuation multiples.
IVF Laboratory Condition and Accreditation
Moderate PositiveA fully accredited, modern IVF lab with current CLIA certification and documented QC protocols creates competitive barriers and avoids immediate post-close capital replacement costs.
Recent Market Trends
PE consolidation by platforms like US Fertility and Inception Fertility has compressed cap rates and elevated multiples since 2021. Expanding state insurance mandates are improving revenue visibility. Post-Dobbs legislative uncertainty around embryo personhood laws is introducing deal structure caution, particularly in Southern states, leading buyers to price regulatory risk into earnout provisions.
Who Buys Fertility Clinics in 2026
Individual Operator / Search Fund
Entrepreneurship through acquisition (ETA), first-time buyers, industry-adjacent operators
What they want: Stable, transferable cash flow in a Fertility Clinic. SBA-eligible business, strong sart/cdc success rate publication, and a seller available for a 12–18 month transition.
Pros for seller
- +SBA 7(a) financing means 10% buyer equity — faster than waiting for institutional capital
- +Buyer works inside the business, maintaining client and staff relationships
- +Deal structure is typically straightforward: cash at close plus seller note
Cons for seller
- −Lower multiples than PE buyers — typically at the low-to-mid end of the range
- −Requires meaningful seller involvement post-close for transition
- −SBA approval timeline adds 60–90 days to closing
PE-Backed Roll-Up Platform
Private equity consolidators building a Fertility Clinic portfolio, regional or national platforms
What they want: Scale, operational quality, and geographic coverage. Strong sart/cdc success rate publication with minimal single-physician dependency. Clean financials, documented systems, and staff who can operate without the selling owner.
Pros for seller
- +All-cash close with no SBA financing contingency or approval delay
- +Highest multiples available for premium businesses
- +Equity rollover option — seller keeps 10–30% stake and participates in platform exit
Cons for seller
- −Extensive 90–150 day due diligence process
- −Post-close integration into a larger platform changes operating culture
- −Usually requires seller to remain in a leadership role for 12–24 months
Strategic Acquirer
Larger Fertility Clinic operators, adjacent-industry buyers adding capacity or geography
What they want: Client relationships, staff, and market position that complement existing operations. SART/CDC Success Rate Publication is especially valuable when it fills a gap the buyer cannot build organically.
Pros for seller
- +Can pay above-model multiples for strong strategic fit
- +Buyer already understands the business — diligence moves faster
- +Shorter transition requirement when operational overlap exists
Cons for seller
- −Fewer competing buyers — less negotiating leverage
- −Non-compete scope is typically broader than PE or individual deals
- −Operations and brand may change significantly post-close
Sample Fertility Clinic Transactions
Two-RE suburban fertility center, SART member, egg freezing and PGT-A services, Progyny contract, clean regulatory history, Southeast market
$2.8M
EBITDA
7.2x
Multiple
$20.2M
Price
Solo-physician IVF clinic, average SART rates, no associate RE, basic service line, Midwest suburban market with strong local brand
$1.7M
EBITDA
5.5x
Multiple
$9.4M
Price
Three-RE regional fertility center, donor egg program, in-house andrology lab, above-average CDC success rates, employer benefit contracts, Mid-Atlantic
$4.2M
EBITDA
8.5x
Multiple
$35.7M
Price
EBITDA Valuation Estimator
Get your Fertility Clinic business value range instantly
Industry: Fertility Clinic · Multiples based on 6x–7x (Established Two-Physician Practice)
Powered by DealFlow OS
dealflow-os.com · Free M&A tools for every stage of the deal
How to Use These Multiples
For Sellers: 4-Step Valuation Walkthrough
- 1
Compile three years of P&L statements and tax returns that reconcile line by line — SBA lenders and institutional buyers both require this, and any unexplained gap triggers diligence delays or price renegotiation.
- 2
Build a normalized EBITDA schedule with every add-back documented: owner W-2 above a market-rate manager salary, personal expenses, one-time items, and non-recurring costs. Undocumented add-backs get cut.
- 3
Address your single-physician dependency before going to market — this is the most common reason Fertility Clinic businesses receive offers at the low end of the 5x–9x range. Buyers identify it in diligence and reprice accordingly.
- 4
Quantify and document your sart/cdc success rate publication with supporting records: contracts, renewal histories, and client revenue breakdowns. This is the primary evidence for commanding a premium multiple — have it ready before the first buyer call.
For Buyers: Validate the Asking Multiple
- 1
Request trailing 12-month and 3-year P&L with bank statement backup before making an offer. If a Fertility Clinic seller cannot produce reconciled financials, that signals what the full diligence process will look like.
- 2
Verify the sart/cdc success rate publication claims independently — pull contract copies, renewal documentation, and client-level revenue data. This is the primary driver of whether this Fertility Clinic is worth 9x or 5x.
- 3
Assess single-physician dependency directly: ask which revenue or client relationships depend on the current owner personally, and what the transition plan is. An exit-ready seller has already worked through this.
- 4
Model your SBA debt service against verified EBITDA before signing the LOI. At current rates, a $1M SBA 7(a) loan runs approximately $13,000/month over 10 years — the business needs at least 1.25x debt service coverage after a market-rate manager salary.
Frequently Asked Questions
Why are fertility clinic multiples higher than most medical practices?
Limited supply of SART-accredited clinics, strong self-pay pricing power, and aggressive PE platform demand create a seller-favorable market pushing multiples well above typical primary care or specialty practice norms.
Does SBA financing apply to fertility clinic acquisitions?
No. Fertility clinics are not SBA-eligible due to passive income characteristics of MSO structures and the complexity of corporate practice of medicine restrictions. Buyers use PE capital, seller notes, or conventional bank financing.
How does a single founding physician affect the sale price?
A solo RE with no associate triggers a 1x–2x multiple discount. Buyers require a signed long-term employment agreement, earnout tied to patient retention, or a seller-financed note to offset key-person departure risk.
What EBITDA normalization adjustments matter most in fertility clinic QoE reports?
Above-market physician compensation, one-time lab equipment purchases, personal expenses run through the practice, and embryo storage revenue timing are the most common add-backs reviewed in a fertility clinic quality of earnings analysis.
More Fertility Clinic Guides
Related Reading
Find Fertility Clinic businesses at the right price
DealFlow OS surfaces acquisition targets with seller signals and outreach angles. Free to join.
No credit card required